We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+4.69%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$329M
AUM Growth
+$19.3M
(+6.2%)
Cap. Flow
-$20.6M
Cap. Flow
% of AUM
-6.26%
Top 10 Holdings %
Top 10 Hldgs %
91.11%
Holding
16
New
1
Increased
4
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$4.77M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$207K |
| 3 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$169K |
| 4 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$124K |
| 5 |
UNIS
Unilife Corporation
UNIS
|
+$32.8K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$11.2M |
| 2 |
CONMED
CNMD
|
+$6.42M |
| 3 |
Orthofix Medical
OFIX
|
+$4.71M |
| 4 |
AVNS
Avanos Medical
AVNS
|
+$514K |
| 5 |
IVC
Invacare Corporation
IVC
|
+$389K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enanta Pharmaceuticals
ENTA
$366M
| $39.8M | 12.07% |
1,104,992
+6,468
| +0.6% | +$207K |
|
2
Gilead Sciences
GILD
$162B
| $37.7M | 11.44% |
532,434
-4,587
| -0.9% | -$305K |
|
|
3
United Therapeutics
UTHR
$25.8B
| $35.4M | 10.75% |
272,996
+38,253
| +16% | +$4.77M |
|
|
SCMP
4
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $29.6M | 8.99% |
2,819,708
+16,570
| +0.6% | +$169K |
|
|
5
Orthofix Medical
OFIX
$477M
| $27.1M | 8.24% |
583,807
-113,571
| -16% | -$4.71M |
|
|
SRGA
6
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $26.1M | 7.93% |
148,836
+871
| +0.6% | +$124K |
|
7
Merck
MRK
$322B
| $24.5M | 7.44% |
400,791
-2,486
| -0.6% | -$151K |
|
|
AVNS
8
DELISTED
Avanos Medical
AVNS
| $22.4M | 6.81% |
570,964
-13,600
| -2% | -$514K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $14.8M | 4.49% |
1,121,066
-29,563
| -3% | -$389K |
|
|
UNIS
10
DELISTED
Unilife Corporation
UNIS
| $13.3M | 4.03% |
+77,079
| New | +$32.8K |
|
|
11
CONMED
CNMD
$1.39B
| $11.5M | 3.5% |
226,497
-129,807
| -36% | -$6.42M |
|
|
VXRT
12
DELISTED
Vaxart
VXRT
| $1.9M | 0.58% |
257,848
| – | – |
|
|
STRR
13
DELISTED
Star Equity Holdings
STRR
| $1.35M | 0.41% |
6,684
| – | – |
|
|
JNP
14
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.23M | 0.37% |
243,128
| – | – |
|
|
15
Amgen
AMGN
$208B
| – | – |
-68,015
| Closed | -$11.2M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Krensavage Asset Management held 16 positions worth $329M, up 6.2% from $310M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Krensavage Asset Management withdrew a net $20.6M in Q2 2017, closing 1 position and reducing 7 holdings. Its most notable exit was Amgen, an estimated $11.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in Unilife Corporation worth $13.3M.
- Krensavage Asset Management's largest Q2 2017 buy was Unilife Corporation: 77,079 shares worth $13.3M.
- Krensavage Asset Management added most to United Therapeutics in Q2 2017, an estimated $4.77M increase.
- Krensavage Asset Management's biggest Q2 2017 reduction was CONMED, cutting an estimated $6.42M.
- Krensavage Asset Management fully exited Amgen in Q2 2017, selling an estimated $11.2M.
- Krensavage Asset Management's ten largest holdings make up 91% of its $329M portfolio in Q2 2017.
- Krensavage Asset Management opened 1 new position and closed 1 in Q2 2017.
- Krensavage Asset Management's portfolio value rose 6.2% quarter-over-quarter to $329M.
Based on Krensavage Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.